Summary The relative contributions of imidazoline-preferring receptors (IPR) and α2-adrenoceptors to hypotensive and bradycardic effects of intracisternal (i.e.) rilmenidine were investigated in conscious rabbits. We compared the antagonist potencies of two α2-adrenoceptor antagonists, 2-methoxy-idazoxan (0.001–10 μg/kg i.e.), which has very low affinity for IPR, and idazoxan (0.003–30 μg/kg i.e.), which has high affinity for blocking IPR. We also compared the i.e. effects of the antagonists on responses to α-methyldopa (α-MD), a drug with centrally acting α2-adrenoceptor agonist metabolites that have no affinity for IPR. Rilmenidine (22 μg/kg i.e.) and α-MD (400 μg/kg i.e.) produced similar decreases in mean arterial pressure (MAP) (ΔAMAP = −23 ± 2 and −24 ± 2%, respectively) and in heart rate (HR) (ΔHR = −11 ± 1 and −9 ± 2%, respectively, n = 30). The hypotension and bradycardia produced by α-MD and rilmenidine were completely reversed by 2-methoxy-idazoxan, but 2-methoxy-idazoxan was 16 and 9 times more potent at restoring MAP and HR, respectively, after α-MD than after rilmenidine. In contrast, idazoxan was more potent in reversing the hypotension elicited by i.e. injections of rilmenidine than that elicited by a-MD. Idazoxan, however, had no effect on rilmenidine-induced bradycardia, but did dose-dependently reverse the decrease in HR produced by α-MD. In separate experiments, we observed that the doses of each antagonist drug in themselves did not modify MAP nor HR significantly, but a 10-fold higher dose of idazoxan (300 μ /kg) caused immediate although brief hypertension and tachycardia. Thus, at “therapeutically relevant” doses, the preferential reversal of rilmenidine's hypotension by idazoxan as compared with 2-methoxy-idazoxan supports a more important contribution of IPR than of α2-adrenoceptors in the central cardiovascular effects of rilmenidine. Furthermore, since 2-methoxy-idazoxan at a high dose (10 μ /kg) completely reversed rilmenidine-induced hypotension suggests that the two receptor systems are likely to be in series along the same cardiovascular autonomic pathways in the brainstem.
No takes yet. Share an insight, caveat, or question.
Sannajust et al. (1994) studied this question.